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Kaposi’s sarcoma herpesvirus (KSHV) belongs to the gamma-2 Herpesviridae and is associated with three neoplastic disorders:
Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD). The viral latency-asso-
ciated nuclear antigen 1 (LANA) is expressed in all latently KSHV-infected cells and is involved in viral latent replication and
maintenance of the viral genome. We show that LANA interacts with the ubiquitin-specific protease USP7 through its N-termi-
nal TRAF (tumor necrosis factor [TNF] receptor-associated factor) domain. This interaction involves a short sequence (amino
acids [aa] 971 to 986) within the C-terminal domain of LANA with strong similarities to the USP7 binding site of the Epstein-
Barr virus (EBV) EBNA-1 protein. A LANA mutant with a deletion of the identified USP7 binding site showed an enhanced abil-
ity to replicate a plasmid containing the KSHV latent origin of replication but was comparable to the wild-type LANA (LANA
WT) with regard to the regulation of viral and cellular promoters. Furthermore, the LANA homologues of two other gamma-2
herpesviruses, MHV68 and RRV, also recruit USP7. Our findings suggest that recruitment of USP7 to LANA could play a role in
the regulation of viral latent replication. The recruitment of USP7, and its role in herpesvirus latent replication, previously de-
scribed for the latent EBNA-1 protein of the gamma-1 herpesvirus (lymphocryptovirus) EBV (M. N. Holowaty et al., J. Biol.
Chem. 278:29987–29994, 2003), may thereby be a conserved feature among gammaherpesvirus latent origin binding proteins.
Kaposi’s sarcoma herpesvirus (KSHV), or human herpesvirus 8, isa gamma-2 herpesvirus (5, 33, 38). KSHV is the causative agent of
Kaposi’s sarcoma and two lymphoproliferative disorders—primary
effusion lymphoma (PEL) and multicentric Castleman’s disease
(MCD) (4, 44). KSHV persists in infected cells predominantly in a
latent state, during which only a small subset of genes is expressed.
Among them, the latency-associated nuclear antigen 1 (LANA), en-
coded by open reading frame 73, is constitutively expressed in all
latently KSHV-infected cells and KSHV-associated malignancies (10,
22, 37).
LANA is a multifunctional protein that plays important roles
in the maintenance of the viral genome, latent genome replication,
and correct episome distribution in dividing cells. It tethers the
viral genome to the host cell DNA by interacting with human
chromatin by means of its N- and C-terminal domains and with
the terminal repeat (TR) region of the viral DNA via its C-terminal
domain. Viral genome maintenance involves interaction with cel-
lular histones and chromatin-associated proteins like MeCP2,
UNG2, BRD2/4, and DEK (24, 34, 35, 48, 51). Like the Epstein-
Barr virus nuclear antigen 1 (EBNA-1) and other viral DNA bind-
ing proteins, LANA recruits additional proteins to allow latent
genome replication, such as members of the origin recognition
complex (ORC) (9, 29, 45).
Additionally, LANA can act as a transcriptional repressor or acti-
vator of both viral and cellular promoters. It interacts with proteins or
protein complexes such as CREB2/ATF4, CBP, mSIN3, or Sp1 (25,
28, 49). LANA also interacts with p53, retinoblastoma protein (pRb),
and glycogen synthase kinase 3 (GSK-3), thereby inhibiting the
activation of p53-dependent promoters, inducing the activation of
E2F target genes, or promoting entry into the S phase of the cell cycle
(13, 14, 36).
The ubiquitin-specific protease 7 (USP7), also called HAUSP
(herpesvirus-associated USP), is a deubiquitinating enzyme that
regulates numerous proteins, including tumor suppressors, DNA
repair proteins, proteins involved in immune responses, viral pro-
teins, and epigenetic modulators. It was identified to be a key
player in the p53-Mdm2 pathway as it can deubiquitinate both
p53 and Mdm2, with higher affinity for Mdm2 leading to Mdm2
stabilization and thereby Mdm2-catalyzed degradation of p53 (7,
8, 21, 26, 27, 43). It was observed that Mdm2 and p53 bind in a
mutually exclusive manner within the N-terminal tumor necrosis
factor (TNF) receptor-associated factor (TRAF)-like domain of
USP7, recognizing the same shallow groove on the USP7 surface
(21, 43). Mdm2 makes more extensive contacts to USP7 than p53,
which accounts for a higher binding affinity (21, 43). This is sup-
ported by competition assays where an Mdm2 peptide efficiently
displaced a p53 peptide (21). Furthermore, consensus peptide se-
quences for recognition by USP7 could be described. Sheng and
colleagues (43) identified P/A-X-X-S (with X as any residue) as the
consensus sequence, with the serine residue being an important
residue for mediating contact to substrates, as recently also con-
firmed for another USP7 substrate (40).
Moreover, USP7 is involved in the regulation of two further
proteins with a regulatory role in the p53-Mdm2 pathway: death-
domain-associated protein DAXX and MdmX (also known as
Mdm4), a structural homologue of Mdm2 (30, 46). The interplay
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between Mdm2 and USP7 seems to be fine-tuned by DAXX, un-
derlining the importance of a tight regulation of USP7 in cell fate
decisions (46).
USP7 was originally identified as an interaction partner of
ICP0 (also named Vmw110), an immediate-early gene of herpes
simplex virus 1 (HSV-1) with a role in the initiation of the viral
lytic life cycle (11). ICP0, a ubiquitin E3 ligase, induces auto-ubiq-
uitination, which is counteracted by USP7, leading to stabilization
of the ICP0 protein (3). ICP0 can also ubiquitinate USP7 and
reduce cellular USP7 levels (2). However, it was shown that the
stabilizing effect of ICP0 deubiquitination by USP7 is dominant
over ICP0-induced degradation of USP7, as no reduction in USP7
levels can be observed when ICP0 is expressed in limiting amounts
(2). In contrast to the cellular USP7 target proteins described so
far (see above), ICP0 binds within the C-terminal domain of USP7
(18).
USP7 was further found to interact with Epstein-Barr virus
EBNA-1, which is a functional homologue of LANA (19). An
EBNA-1 mutant unable to interact with USP7 shows increased
replication of the latent EBV origin and decreased transcriptional
activation but has no effect on the segregation function of EBNA-1
(19). Additionally, it was observed that USP7 forms a complex
with DNA-bound EBNA-1 and that the DNA binding activity of
EBNA-1 is increased by USP7 (41). USP7 further shows aug-
mented recruitment to the FR (family of repeats) element of oriP,
the origin of latent EBV replication (41), and can decrease H2B
ubiquitination together with GMPS (guanosine 5= monophos-
phate synthetase), thereby influencing gene expression (41, 47).
Thus, there is some evidence that the interaction of USP7 and
EBNA-1 regulates plasmid maintenance and/or latent replication
during EBV infection (41). It was further shown that EBNA-1
binds with higher affinity to the N-terminal domain of USP7 than
p53, indicating that EBNA-1 competes with p53 for USP7 binding
during infection. This is supported also by structural studies (39,
43) and may have an effect on p53 function (18).
Here, we show that LANA, as well as the LANA homologues of
two other gamma-2 herpesviruses, also interact with USP7. The
residues critical for USP7 binding are predominantly located in
the C-terminal domain of LANA, in a short region displaying high
sequence homology to EBNA-1. Similar to EBNA-1, LANA inter-
acts with the N-terminal part of USP7, which is also involved in
the interaction with the USP7 targets p53, MdmX, and Mdm2.
Similar to what was previously shown for EBV, latent viral repli-
cation of the KSHV genome depends on USP7, while LANA tran-
scriptional activity is not affected by USP7 binding.
MATERIALS AND METHODS
Expression plasmids. All full-length LANA constructs were in a pcDNA
3.1 background. The numbering of amino acids of LANA corresponds to
the KSHV BC-1 sequences (38). An expression vector for full-length
LANA was described previously (50). The sequences of PCR primers used
in this study, and their numbered designations, are listed in Table 1. The
mutant with deletion of amino acids (aa) 971 to 986 was cloned by over-
lapping PCR with primers 1, 2, 3, and 4. For the cLANA  971-986 con-
struct, primer 5 was used for overlapping PCR instead of primer 1. LANA
GST fusion proteins used in glutathione S-transferase (GST) pulldown
experiments represented different segments of the C-terminal domain (aa
951 to 1162) of LANA and were described previously (35). Additionally,
the construct C6a was generated by PCR using primers 6 and 7. To obtain
the cLANA 971-986 mutant in the GST vector backbone, another over-
lapping PCR was performed with primers 5, 3, 4, and 8.
Mammalian LANA constructs harboring only the N- or C-terminal
domain of LANA were cloned with the following primers (in myc epitope-
containing pcDNA3myc provided by S. Mittnacht, London, United King-
dom, or HA-containing pVR1255 provided by J. Stewart, Liverpool,
United Kingdom): primers 9, 10, 11, 12, 2, and 13. For the cLANA 977-
980/AAAA mutant, a potential USP7 binding motif in the C-terminal
domain of LANA (aa 977 to 980) was changed to four alanines by site-
directed mutagenesis using primers 14 and 15.
For electrophoretic mobility shift assays (EMSAs), cLANA was cloned
in pGEX-6p-1 by PCR with primers 13 and 16, with full-length LANA as
the template. Mutation of the PYG motif (aa 1065 to 1067) to alanine was
introduced by site-directed mutagenesis using primers 17 and 18.
Full-length RRV Orf73 (1,347 bp) of RRV isolate 17577 tagged N
terminally with a myc epitope was provided by R. Searles (Portland, OR).
The MHV68 Orf73 construct cloned from murine herpesvirus 4 strain
TABLE 1 Sequences of primers used for cloning different expression vectors
Primer no. Primer name Sequence
1 LANA start for 5=- ATA GAA TTC ATG GCG CCC CCG GGA ATG-3=
2 LANA end XhoI rev 5=- AGA CTC GAG TTA TGT CAT TTC CTG TGG AGA G-3=
3 LANA aa 970 rev delta 5=- TCT GTG GGG TGG TGA TGT TCT GAG TGT ATT ATC TCC TGG TGG-3=
4 LANA aa 987 for delta 5=- AGT AGC CCA CCA GGA GAT AAT ACA CTC AGA ACA TCA CCA CCC CAC AG-3=
5 LANA aa 934 EcoRI for 5=- AGA GAA TTC GAA GAG CCC ATA ATC TTG-3=
6 LANA GST C6a for 5=- AGA GAA TTC CCA GAC GAT GAC CCA CAA C-3=
7 LANA GST C6a rev 5=- AGA GCG GCC GCT CAT ACA TAG CGG-3=
8 LANA end NotI rev 5=- AGA GCG GCC GCT TAT GTC ATT TCC TGT GGA GAG-3=
9 LANA aa 1 for 5=- AGA GTC GAC ACC ATG GCG CCC CCG GGA ATG-3=
10 LANA aa 340 rev 5=- AGA GCG GCC GCG CTC CTC ATC TGT CTC CTG-3=
11 LANA aa 934 SalI for 5=- AGA GTC GAC ACC ATG GAA GAG CCC ATA ATC TTG-3=
12 LANA aa 1162 rev 5=- AGA GCG GCC GCG TGT CAT TTC CTG TGG AGA G-3=
13 LANA aa 934 BamHI for 5=- AGA GGA TCC GAA GAG CCC ATA ATC TTG-3=
14 LANA 4A aa 977-980 for 5=- C GAT GAC CCA CAA GCT GCC GCA GCT CGC GAA TAC CGC-3=
15 LANA 4A aa 977-980 rev 5=- GCG GTA TTC GCG AGC TGC GGC AGC TTG TGG GTC ATC G-3=
16 LANA end EcoRI rev 5=- ATA GAA TTC TTA TGT CAT TTC CTG TGG AGA G-3=
17 LANA aa 1065-67 for 5=- GAT TTT TTG GGG CAA TGA CGC AGC CGC ACT TAA AAA ATT ATC TCA GG-3=
18 LANA aa 1065-67 rev 5=- CCT GAG ATA ATT TTT TAA GTG CGG CTG CGT CAT TGC CCC AAA AAA TC-3=
19 USP7 aa 56 for 5=- AGA GGA TCC GAG GAG GAC ATG GAG GAT G-3=
20 USP7 aa 205 rev 5=- AGA CTT AAG TTA CCA CGC AAC TCC ATG GGG AGC-3=
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68-infected cells in the HA-tag-containing pVR1255 vector was provided
by J. Stewart.
The USP7 expression plasmid expressing GFP-tagged USP7 was
kindly provided by Roger Everett, Glasgow, United Kingdom. An N-ter-
minal USP7 construct was cloned based on the full-length construct by
PCR with primers 19 and 20 into a GST fusion vector (pGEX-6p-1).
The plasmid containing the TR region of the KSHV genome was de-
scribed previously (50). This plasmid was used to generate a 1 TR lucif-
erase reporter vector (51).
The cyclin E luciferase reporter vector consisting of the human cyclin
E promoter region cloned in front of a luciferase gene (in pGL2Basic) was
from R. Weinberg’s laboratory (Cambridge, MA) (16). The p53 luciferase
reporter construct containing the p53-responsive promoter region of the
humanmdm2 gene (in pGL2Basic) was provided by M. Dobbelstein (Göt-
tingen, Germany), as was an expression construct for HA-tagged human
p53 in a pcDNA backbone.
Cells and cell culture. HEK 293, HEK 293-T, and p53-deficient H1299
cells were grown in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), 50 IU/ml penicillin, and 50
g/ml streptomycin at 37°C in a 5% CO2 incubator.
Suspension cells such as BJAB and BJAB stably infected with KSHV (S.
Kati, S. Hu¨bner, T. Rotha¨mel, and T.F. Schulz, unpublished data), as well
as the PEL cell lines BC1 and BC3, were grown in RPMI 1640 (containing
L-glutamine) supplemented with 20% fetal calf serum (FCS), 50 IU/ml
penicillin, and 50 g/ml streptomycin at 37°C in a 5% CO2 incubator.
For transfection, adherent cells were grown to subconfluence in six-
well plates and transfected with the indicated expression constructs with
FuGENE transfection reagent (Roche) according to the manufacturer’s
instructions.
SDS-PAGE and immunoblotting. Forty-eight hours after transfec-
tion with the indicated expression plasmids, cells were lysed in 300 l
TBST lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100) per well. Cleared lysates were subjected to SDS-PAGE,
and proteins were detected by Ponceau S staining or immunoblotting.
The following antibodies were used: mouse or rabbit -GFP (Clon-
tech), mouse -actin (Millipore), rat -LANA (ABI), mouse or rat -HA
(Roche), human-KS serum from KSHV-seropositive patients, and poly-
clonal rabbit serum detecting GST fusion proteins.
GST pulldown assay. For GST pulldown experiments, Escherichia coli
Rosetta cultures transformed with GST expression plasmids or GST only
were grown at 37°C in LB medium plus ampicillin and chloramphenicol.
Cultures were induced at an optical density at 600 nm of 0.4 to 0.6 with 1
mM isopropyl--D-thiogalactopyranoside (IPTG) and harvested by cen-
trifugation 5 h after induction. Pelleted cells were resuspended in 500 l
phosphate-buffered saline (PBS) with protease inhibitors, sonicated for 1
min on ice, supplemented with 1% Triton X-100, and incubated for 10
min at 4°C. Following centrifugation, the supernatant was incubated with
80 l glutathione-Sepharose beads (Amersham Biosciences) overnight at
4°C. Beads were washed three times with PBS plus protease inhibitors and
analyzed on a Coomassie-stained gel to calculate equal amounts of GST
fusion proteins. HEK 293-T cells were transfected and lysed as mentioned
above. Cleared lysate (300 l) was incubated with either GST fusion pro-
teins or GST control protein for 1 h at room temperature (RT). Beads were
washed six times with PBS and analyzed by SDS-PAGE and Western blot-
ting.
Coimmunoprecipitation. HEK 293-T cells were cotransfected with
plasmids encoding the interaction partners of interest; the amounts used
are indicated in the figure legends. Forty-eight hours after transfection,
cells were washed once in cold PBS and lysed in 300 l of TBST buffer
containing protease inhibitors per well of a six-well plate. For precipita-
tion of endogenous proteins, suspension cell lines were also lysed in 300l
TBST buffer containing protease inhibitors.
The monoclonal antibodies -GFP (Clontech), -HA (Roche), and
-LANA (ABI) were immobilized on protein A or G Sepharose beads
(Amersham). For precipitation of myc-tagged proteins, c-myc monoclo-
nal antibody-agarose beads (Clontech) were used.
An aliquot of 40 l cleared cell lysates was taken (input control), and
the remaining 260 l were incubated overnight on a roller at 4°C with 12
l of beads coupled with antibody to precipitate the protein of interest.
Afterwards, samples were centrifuged (1,100 g, 30 s) and washed exten-
sively with 700 l TBST (supplemented with 1% sodium deoxycholate, if
higher stringency was necessary). Finally, beads were boiled with 30 l of
5 loading buffer (62.5 mM Tris-HCl, pH 6.8, 2% [wt/vol] SDS, 10%
glycerol, 50 mM dithiothreitol [DTT], 0.01% [wt/vol] bromophenol
blue) for 3 min and 20 l of the samples was analyzed by SDS-PAGE. As
input control, 1/10 of the input lysate was loaded.
Transient replication assay. Short-term replication assays were per-
formed with HEK 293 cells cotransfected with 500 ng expression vector
containing 1 TR and 250 ng pBluescript (input control) plus 500 ng of
LANA expression constructs or the empty vector pcDNA3. Thirty hours
after transfection, the cells were split 1:2 and allowed to grow for a further
48 h. Cells were then harvested in 150l of lysis buffer per well of a six-well
plate (10 mM Tris-HCl, 10 mM EDTA, 0.6% SDS), and duplicate wells,
obtained by splitting, were pooled. Chromosomal DNA was precipitated
overnight with 0.85 M NaCl. An aliquot was collected from the superna-
tant to determine the expression levels of the different LANA constructs
by immunoblotting. Plasmid DNA was purified from the supernatant
using phenol-chloroform extraction and precipitated afterwards with
ethanol. Finally, plasmid DNA was resuspended in H2O. A total of 90% of
the DNA was digested with 40 U KpnI and 40 U of DpnI for 48 h, while the
remaining 10% was digested with 10 U KpnI to measure input DNA. The
digested DNA was separated on a 0.8% agarose gel and analyzed by South-
ern blotting with a 962-bp fragment of pBluescript used as an alkaline
phosphatase-labeled probe (AlkPhos Direct Labeling and Detection Sys-
tem with CDP-Star; GE Healthcare).
EMSA. IRD700-labeled oligonucleotides (IBA GmbH, Göttingen,
Germany) were prepared as follows: 5 l of each oligonucleotide (LANA
BS top, 5=-GAG GCG GCG CGC GGC CCC ATG CCC GGG CGG GAG
GCG CCG CAG GCC CCG GCG GCG TCC CCG GC-3=; LANA BS bot-
tom, 5=-GCC GGG GAC GCC GCC GGG GCC TGC GGC GCC TCC
CGC CCG GGC ATG GGG CCG CGC GCC GCC TC-3=) was mixed with
2 l of 10 annealing buffer (200 mM Tris-HCl, pH 7.6, 500 mM NaCl,
100 mM MgCl2), and the volume was adjusted to 20 l with H2O. This
annealing reaction mixture was incubated for 5 min at 95°C, 10 min at
65°C, 10 min at 37°C, and 10 min at 20°C and cooled to 4°C. The annealed
oligonucleotides were diluted 1:5 for the binding reaction.
For binding, 0.5 to 2l of LANA GST fusion proteins was added to 1.5
l binding buffer (300 mM Tris-HCl, pH 7.9, 500 mM KCl, 100 mM
MgCl2, 10 mM DTT, 10 mM EDTA) as well as 1.5l 100% glycerol, 1.5l
of a 2.5% Tween 20 solution, 0.75 l poly(dI-dC) (1 mg/ml), 0.75 l of a
10-mg/ml solution of bovine serum albumin (BSA), and 1 l of the an-
nealed oligonucleotides. Reactions were made up with H2O to a 15-l
final volume and incubated for 30 min at RT in the dark. For competition,
a 100 to 200 excess of unlabeled probe was added to the band shift
mixture. Supershifts were carried out with 4 l of a polyclonal LANA
rabbit serum or a rabbit antibody not reacting with LANA for a control.
For supershift, binding reaction mixtures were incubated for another 30
min after addition of the antibodies.
A 4% native acrylamide gel was prerun for 1 h at 160 V in 1 TBE.
Afterwards, the band shift reaction mixtures were loaded onto the gel and
separated for 2 h at 160 V. After the run, gels were immediately analyzed
with the Odyssey infrared imaging system from Licor Biosciences.
Luciferase reporter assay. For luciferase reporter assays, HEK 293,
HEK 293-T, or H1299 cells were transiently cotransfected in duplicates
with 50 ng of reporter plasmid and expression constructs as indicated in
the figure legends. Forty-eight hours after transfection, cells were washed
once with PBS and lysed in 300l reporter lysis buffer (Promega) per well
of a six-well plate. Luciferase activity was measured in cleared lysates with
USP7 Inﬂuences KSHV Episomal Replication
June 2012 Volume 86 Number 12 jvi.asm.org 6747
a luciferase system in accordance with the manufacturer’s instructions
(Promega).
RESULTS
LANA interacts with USP7. USP7 was previously reported to in-
teract with two herpesviral proteins, HSV-1 ICP0 and EBV
EBNA-1, and to be important for the life cycle of both viruses.
Since LANA is a functional homologue of EBNA-1, we investi-
gated whether LANA could also interact with USP7. We trans-
fected HEK 293-T cells with a GFP-tagged expression construct
for USP7 as well as an expression vector for LANA and precipi-
tated protein complexes with -LANA antibody coupled to pro-
tein G-Sepharose beads. Following washing of the immunocom-
plexes, the interaction was analyzed via immunoblotting using an
-GFP antibody. Transfection of empty vector served as a nega-
tive control. We found that LANA is capable of interacting with
USP7 (Fig. 1A). This observation could be confirmed in a recip-
rocal coimmunoprecipitation experiment, in which LANA was
found in a complex with precipitated USP7 (Fig. 1B). Addition-
ally, the interaction of LANA and USP7 could be verified with
coimmunoprecipitation experiments using naturally KSHV-in-
fected PEL cell lines, as well as BJAB cells stably infected with
recombinant KSHV virus (Fig. 1C and D). Endogenously ex-
pressed (untransfected) USP7 interacted with LANA in KSHV-
infected cells, but not in the uninfected control BJAB cells (Fig.
1C), and in all PEL cell lines tested (BC1, BC3) (Fig. 1D).
Mapping of the USP7 binding site of LANA. Following the
observation that LANA interacts with USP7, we investigated
which domains of both proteins are involved in the interaction.
We started by mapping the USP7 binding site in LANA to the
N-terminal or C-terminal domain. USP7 coimmunoprecipitates
with the C-terminal domain of LANA but not with the N-terminal
domain (Fig. 2A). To further determine the residues of LANA
critical for USP7 binding, GST pulldown experiments were per-
formed. Truncated versions of the C-terminal domain of LANA
fused to GST (Fig. 2B) were expressed in bacteria, isolated, and
purified by binding to GST beads, and their interaction with eu-
karyotically expressed plasmids of GFP-tagged USP7 or the ap-
propriate empty vector was investigated. In the GST pulldown
experiments, USP7 interacted with the constructs C4, C5, and C6
(Fig. 2B and C). In addition, the small LANA fragment C6a, com-
prising a region of 16 aa, interacted with USP7 (Fig. 2B and D).
This region, which is located between aa 971 and 986, contains a
PGPS motif (Fig. 3) that corresponds to the consensus sequence
P/A-X-X-S for USP7 binding found by Sheng and coworkers (43).
An alignment of the USP7 binding site of LANA with the pre-
viously described USP7 binding site in EBNA-1 (19) showed that
the consensus motif, as well as further residues of the identified
LANA region involved in USP7 binding, are conserved in
EBNA-1. Within the fragment C6 (aa 951 to 1006), the sequence
of aa 971 to 986 (C6a) is the only one to show significant sequence
homology between LANA and EBNA-1 (Fig. 3). These sequence
similarities emphasize the importance of these residues for the
interaction with USP7.
As depicted in Fig. 4, removal of aa 971 to 986 from the C-ter-
minal LANA domain abolished binding of LANA to USP7 in GST
pulldown experiments (Fig. 4A) as well as in coimmunoprecipi-
tation experiments (Fig. 4B). In addition, the substitution of the
PGPS motif in LANA (aa 977 to 980) with four alanine residues
eliminated the binding of USP7 to the LANA C-terminal domain
in coimmunoprecipitation assays (Fig. 4B). This finding confirms
the importance of LANA aa 971 to 986, and in particular aa 977 to
980, for binding to USP7.
In the next step, the deletion of the region aa 971 to 986 was
introduced into a full-length LANA construct by overlapping
PCR. The full-length LANA construct harboring the deletion of
the potential USP7 binding site (LANA  971–986) showed a
strongly reduced binding to USP7 (Fig. 4C). The signal intensities
of the immunoprecipitated USP7 bands in Fig. 4C (second panel
from bottom) were quantified with ImageJ and normalized to the
upper LANA band in the bottom panel of Fig. 4C, indicating a
residual interaction of 29% (data not shown). This residual bind-
ing cannot be attributed to an additional USP7 binding site in the
N-terminal domain of LANA, as the N-terminal domain of LANA
was not found to interact with USP7 (Fig. 2A).
LANA binds to the N-terminal domain of USP7. Most USP7
substrates and interaction partners like Mdm2, Mdmx, p53, and
EBNA-1 were shown to bind to the N-terminal TRAF domain of
USP7 (18, 21, 39, 40, 43). In contrast, the HSV-1 protein ICP0
interacts with the C-terminal part of USP7, a domain of unknown
function (18). We investigated whether LANA is able to interact
with the N-terminal domain of USP7 in GST pulldown experi-
ments. The N-terminal domain of USP7 was expressed as a GST
fusion protein in bacteria and purified via the GST tag. Lysates of
cells transiently transfected with expression constructs of LANA
or LANA  971–986 were incubated with adjusted amounts of
GST-USP7 protein coupled to beads. After washing, protein in-
teraction was analyzed by immunoblotting. These experiments
revealed that LANA can interact with the N-terminal TRAF do-
main whereas the LANA mutant lacking the USP7 binding site (aa
971 to 986) is not able to bind to the N-terminal domain of USP7
(Fig. 4D). This result suggests that LANA resembles EBNA-1, p53,
Mdm2, and MdmX in targeting the N-terminal TRAF domain of
USP7 and underlines the importance for the LANA region (aa 971
to 986) for interaction with the TRAF domain of USP7.
Deletion of aa 971 to 986 increases the ability of LANA to
replicate latent viral DNA. As binding of USP7 to a LANA mutant
lacking aa 971 to 986 is strongly reduced (in coimmunoprecipita-
tion assays) or absent (in GST pulldown assays), this LANA mu-
tant was used to study the functional importance of the USP7-
LANA interaction. LANA mediates episome persistence by
tethering the viral episome to human chromatin and thus is im-
portant for latent replication. LANA binds via its C-terminal do-
main to two regions in the terminal repeats (TRs) of the KSHV
genome, which are named LANA binding sites 1 and 2 (LBS1 and
LBS2) (20). LANA is also sufficient to replicate a TR-containing
plasmid in cells in a short-term replication assay (17, 20, 29, 51).
Therefore, the mutant lacking the USP7 binding site (aa 971 to
986) was tested in a transient replication assay to analyze its rep-
lication ability.
The LANA mutant lacking aa 971 to 986 replicated a plasmid
containing the KSHV latent origin of replication more efficiently
than the wild-type LANA (LANA WT) (Fig. 5A). Quantification
of the relative band intensity observed in three independent ex-
periments suggests an approximately four times stronger replica-
tion by LANA  971–986 in comparison to LANA WT (Fig. 5B).
Increased replication ability of LANA971–986 is not due to
altered DNA binding capacity. To investigate if the increased rep-
lication activity of the LANA mutant lacking the USP7 binding site
(aa 971 to 986) could be explained by differences in the ability of
Jäger et al.
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FIG 1 LANA interacts with USP7. (A) The LANA expression construct and a plasmid encoding GFP-tagged USP7, or the appropriate empty vectors, were
cotransfected in equal amounts (1g each) in 293-T cells. Cells were lysed after 48 h, and protein complexes were immunoprecipitated as described in Materials
and Methods with -LANA antibody coupled to protein G-Sepharose beads. After extensive washing, beads were analyzed by SDS-PAGE and immunoblotting
using -LANA and -GFP antibodies. (B) In a reciprocal coimmunoprecipitation experiment, protein complexes were precipitated with -GFP antibody
coupled to protein A-Sepharose beads and the interaction was visualized by staining the immunoblot with an antibody to LANA or GFP as a control. (C)
Coimmunoprecipitation (Co-IP) of endogenous (i.e., not transfected) LANA with USP7 in BJAB cells stably infected with recombinant KSHV virus (BJAB rK).
Parental BJAB and duplicate samples immunoprecipitated with a control IgG served as control. Co-IP and IB were performed as described for panel A. (D)
Coimmunoprecipitation of endogenous LANA with endogenously expressed USP7 in different PEL cell lines. As a control, duplicate samples were immuno-
precipitated with a control IgG. Co-IP and IB were performed as described for panel A.
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both LANA proteins to bind DNA, EMSAs (electrophoretic mo-
bility shift assays) were performed. Therefore, a fluorescently la-
beled (IRD700) oligonucleotide harboring both LBS-1 and LBS-2
was used. The oligonucleotide was incubated with previously ex-
pressed and purified GST-tagged cLANA proteins in the EMSA
binding reaction. Protein complexes were analyzed on a native
polyacrylamide gel, and bands were detected via fluorescence.
The C-terminal LANA domain lacking aa 971 to 986 bound to
DNA to the same extent as cLANA WT (Fig. 5C). For both LANA
proteins, a pattern of shifted bands was observed, of which those
indicated by arrows in Fig. 5C are considered to represent specific
shifts. Application of unlabeled oligonucleotide in great excess
efficiently competed with binding of cLANA to DNA, and the
bands seen in the presence of WT cLANA could be “supershifted”
using an antibody to LANA. These results indicate the specific
nature of the observed bands. As an additional control, a LANA
mutant with a PYG motif mutated to three alanine residues was
included; this mutant had previously been reported to abolish
binding to the LBS regions (23). As expected, this mutant did not
interact with DNA (Fig. 5C).
USP7 does not influence the transactivation function of
LANA. LANA acts as a transcriptional repressor or activator of
several cellular and viral genes. Therefore, we analyzed the possi-
ble influence of USP7 binding on the role of LANA as a transacti-
FIG 2 The region aa 971 to 986 of LANA is sufficient for USP7 binding. (A) Immunoprecipitation experiments with the N-terminal (aa 1 to 340) or C-terminal
(aa 934 to 1162) domain of LANA. The different LANA expression constructs containing an HA-tag and a plasmid encoding GFP-tagged USP7 were cotrans-
fected in equal amounts (1 g each) in 293-T cells. As a control, the appropriate empty vectors were transfected. Immunoprecipitations were carried out as
described in the legend to Fig. 1 and Materials and Methods. (B) Schematic representation of the GST-tagged truncated versions of the C-terminal domain of
LANA (aa 951 to 1162) used in this study. and (), interaction and weak interaction, respectively, with USP7;, lack of interaction. (C and D) GST pulldown
experiments performed with LANA-GST fusion proteins (aa 951 to 1162) expressed in bacteria. Purified and adjusted amounts of each protein were incubated
with eukaryotic cell lysate of 293-T cells previously transfected with an expression construct encoding GFP-tagged USP7 (top) or GFP alone (middle); input for
both experiments is shown in the left of panel C. After extensive washing, protein interaction was analyzed by SDS-PAGE and immunoblotting using an -GFP
antibody. Expression of GST alone and GST fusion proteins was verified by Ponceau S staining.
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vator or repressor. Since LANA plays a role in E2F-dependent
transcription, we examined the effect of USP7 binding on the
activation of the cyclin E promoter, as previously shown (36). The
mutant LANA  971–986 was able to activate the cyclin E pro-
moter to levels comparable to those achieved by LANA WT (Fig.
6A). Second, the full-length LANA mutant lacking the identified
USP7 binding site (LANA  971–986) (Fig. 6B) and the corre-
sponding C-terminal mutant (cLANA  971–986) (data not
shown) were analyzed for their ability to modulate the p53-depen-
dent activation of a p53-responsive promoter, known to be re-
pressed by LANA (13), in p53-deficient H1299 cells. Neither of the
LANA mutants was compromised in its ability to repress p53-
dependent transcription (Fig. 6B and data not shown) in compar-
ison to LANA WT.
LANA also represses the promoter/enhancer activity of the TR
promoter region in the KSHV genome (51). We analyzed the im-
pact of the LANA  971–986 mutant on a TR reporter vector in
HEK 293 cells. Both the LANA WT protein and the mutant lacking
the USP7 binding site (aa 971 to 986) inhibited the TR reporter
vector (Fig. 6C). Taken together, these findings indicate that re-
cruitment of USP7 to LANA does not influence LANA transcrip-
tional activation or repression and does not impact on the regu-
lation of p53-dependent transcription by LANA.
USP7 interacts with the Orf73 proteins of MHV68 and RRV.
We next explored whether homologous Orf73 proteins from KSHV-
related gammaherpesviruses could also interact with USP7. We fo-
cused on the Orf73 proteins from murine herpesvirus 68 (MHV68)
as well as rhesus rhadinovirus (RRV). Expression constructs for both
proteins were cotransfected with a USP7 expression construct or the
corresponding empty vector. Protein complexes were precipitated
via tags fused to the Orf73 proteins and analyzed on Western blots. In
each experiment, a C-terminal LANA construct harboring the same
tag served as a positive control. Both proteins, MHV68 Orf73 (Fig.
7A) and RRV Orf73 (Fig. 7B), interacted reproducibly with USP7 in
coimmunoprecipitation experiments. Together with the previously
investigated role of USP7 in the function of EBV EBNA-1, these find-
ings suggest that the interaction of USP7 with Orf73 proteins is con-
served among different gammaherpesviruses and underlines the pos-
sible importance of this interaction for the viral latent life cycle.
DISCUSSION
KSHV can establish a lifelong persistent infection in humans.
LANA is involved in virus persistence, as it tethers the viral epi-
some to human chromatin. LANA binds the TR region of the
KSHV genome and different histones of the human chromatin (1,
6, 15), and it is also involved in latent replication of the viral
genome. To ensure viral persistence, LANA interacts with differ-
ent cellular proteins. We observed that LANA, as well as the LANA
homologues of two other gamma-2 herpesviruses, MHV68 and
RRV, recruits the deubiquitinating enzyme USP7 (Fig. 1 and 7).
Together with previous studies on the recruitment of USP7 by
EBNA-1, our findings suggest that USP7 is a cellular protein which
plays an important role during gammaherpesvirus latency. The
importance of USP7 is illustrated by the multitude of USP7 targets
identified so far, which include several transcription factors (e.g.,
FOXO4), tumor suppressor proteins (e.g., PTEN, p53), and epi-
genetic modifiers (e.g., DNMT1). In short, USP7 is involved in
cellular responses to various stress stimuli and in maintaining cel-
lular homeostasis. Disregulation of USP7 is associated with dis-
eases such as cancer and neurodegenerative disorders.
In the case of HSV-1 and EBV, the function of USP7 is thought
to include the stabilization of HSV-1 ICP0 or to ensure p53 deg-
radation in EBV-infected cells, respectively (2, 3, 18, 39, 43). We
wanted to elucidate the functional importance of the LANA-USP7
interaction and mapped the binding site of USP7 on LANA in
order to create a LANA mutant deficient for USP7 binding. This
LANA mutant was used to study the role of USP7 recruitment to
LANA. The C-terminal domain of LANA alone is able to mediate
the interaction with USP7 (Fig. 2), and mapping of the USP7
binding site was achieved with a set of truncated C-terminal
LANA constructs (Fig. 2B to D). This led to the identification of a
small region of 16 aa localized between aa 971 and 986, which still
interacts with USP7 (Fig. 3). In turn, the deletion of this region
from the C-terminal domain of LANA abolishes interaction with
USP7 (Fig. 4). Additionally, we assessed whether deletion of the
identified USP7 binding region (aa 971 to 986) abrogated binding
to USP7 in the context of full-length LANA. This LANA mutant
retained some residual interaction with USP7 in coimmunopre-
cipitation assays, but it failed to interact with the USP7 TRAF
domain in GST pulldown assays (Fig. 4C and D). The residual
binding could not be attributed to an additional USP7 binding site
in the N-terminal domain of LANA (Fig. 2A), although possible
USP7 binding sites, according to the USP7 consensus binding mo-
tif (43), are present in the N-terminal part of LANA (not shown).
It is possible that residual binding of USP7 to the LANA mutant
occurs indirectly via another protein binding both LANA and
USP7. A potential candidate could be p53, which was shown to
interact directly with LANA (13) but is also a substrate of USP7.
The identified USP7 binding region was found to be conserved
in EBNA-1, which is a functional homologue of, but displays only
limited sequential homology to, LANA (Fig. 3). Within the USP7
binding region of LANA and EBNA-1 several amino acids are
identical, highlighting the conservation of the USP7 binding site
in LANA and EBNA-1.
This USP7 binding region in LANA centers on a PGPS motif
that corresponds to published consensus sequences (21, 43). Sub-
stitution of this PGPS motif with alanines eliminated the binding
of USP7 to the C-terminal domain of LANA (Fig. 4B). Taken
together, these interaction studies revealed a potential USP7 bind-
FIG 3 Alignment of the USP7 binding regions of LANA and EBNA-1. Align-
ment (originally generated with ClustalW) shows the described USP7 binding
site of EBNA-1 (19) in comparison to the identified USP7 binding site in the
C-terminal domain of LANA. *, Conserved amino acids; :, conserved substi-
tutions; ., semiconserved substitutions. The rectangle marks the region aa 971
to 986.
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FIG 4 Deletion of aa 971 to 986 from the C-terminal domain of LANA abolishes or reduces USP7 binding. (A) LANA constructs harboring a GST tag were
expressed in bacterial cells, bound to glutathione-Sepharose 4B beads overnight, and washed, and adjusted amounts were incubated for 1 h with lysates of 293-T
cells transiently expressing either GFP-tagged USP7 or the empty GFP vector following transfection with the respective expression construct. After extensive
washing steps, beads were analyzed by SDS-PAGE and immunoblotting using an -GFP antibody (right panel, input: left panel). Expression of GST alone and
GST fusion proteins was verified by Ponceau S staining. (B) Western blots showing the results of immunoprecipitation experiments. Different LANA expression
constructs containing an HA tag with either the deletion of aa 971 to 986 or an alanine substitution of the potential USP7 binding motif (aa 977 to 980 in cLANA
977–980/AAAA) and a plasmid encoding GFP-tagged USP7 were cotransfected in equal amounts (1 g each) in 293-T cells. As a control, the appropriate empty
vectors were transfected. Cells were lysed 48 h posttransfection, and protein complexes were immunoprecipitated with-HA antibody coupled to protein-A-Sepharose
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ing site in the C-terminal domain of LANA between aa 971 and
986, including a PGPS motif that mediates contact to USP7.
With the exception of ICP0, USP7 interacts with its partners
through the N-terminal TRAF domain (19). We observed that
LANA also binds to the N-terminal TRAF domain of USP7 (Fig.
4D), indicating an interacting pattern similar to those of EBNA-1,
p53, MdmX, and Mdm2. Nevertheless, we cannot exclude that
further USP7 regions are involved in the interaction with LANA.
To investigate the functional importance of the interaction be-
tween LANA and USP7, we compared LANA WT with the dele-
tion mutant lacking aa 971 to 986 in functional assays. A clear
effect of USP7 recruitment to LANA was observed when using an
beads as described in Materials and Methods and analyzed by immunoblotting using -HA (cLANA) and -GFP (USP7) antibodies. (C) The LANA expression
constructs and a plasmid encoding GFP-tagged USP7 were cotransfected in equal amounts (1 g each) in 293-T cells. As a control, the corresponding empty
vectors were transfected. Cells were lysed after 48 h, and protein complexes were precipitated with -LANA antibody coupled to protein-A-Sepharose beads.
After extensive washing, beads were analyzed by SDS-PAGE and immunoblotting using an-GFP antibody. (D) LANA binds to the N-terminal domain of USP7.
The GST fusion construct of the N-terminal domain of USP7 was expressed in bacteria, purified, and incubated with eukaryotic cell lysate of 293-T cells
previously transfected with expression constructs encoding LANA or LANA 971–986. After extensive washing, protein interaction was analyzed by SDS-PAGE
and immunoblotting using an -LANA antibody (top right). Equal amounts of GST and GST-USP7 were verified by probing the membrane with an antibody
to GST (bottom right).
FIG 5 The LANA mutant lacking aa 971 to 986 shows enhanced replication of a plasmid containing the KSHV origin of latent replication. (A) Transient
replication assay. 293 cells were cotransfected in duplicates with expression plasmids of LANA or the LANA mutant lacking the USP7 binding site (aa 971 to 986),
a plasmid containing one TR subunit, and the empty vector pBluescript as a transfection control. Cells were split 1:2 around 30 h posttransfection and harvested
72 h posttransfection. Plasmid DNA was precipitated and isolated by phenol-chloroform extraction. Replicated plasmid DNA was distinguished from transfected
plasmid DNA by digestion with the methylation-sensitive enzyme DpnI. DNA bands were separated in an agarose gel and visualized by Southern blotting (top
two panels). Detection of expression of LANA proteins used in the experiment with an -LANA antibody (bottom panel). (B) Quantification of the relative
replication mediated by LANA or LANA  971–986 calculated with ImageJ based on relative band intensity. The data shown represent an average value from
three independent experiments. The difference in replication was calculated to be significant using a one-sample t test (two sided, P 0.01). (C) The GST fusion
proteins cLANA, cLANA PYG/AAA, and cLANA  971–986 as well as GST alone as control were expressed in bacterial cells, precipitated by glutathione-
Sepharose 4B beads, and eluted with glutathione after several washing steps. The purified GST proteins were subjected to SDS-PAGE and visualized by Coomassie
staining to adjust protein amounts for the binding reaction (left panels). Electrophoretic mobility shift assays were carried out with IRD700-labeled double-
stranded oligonucleotides containing LBS-1 and LBS-2. Reactions were performed with the purified and adjusted GST proteins. Unlabeled oligonucleotides were
used for competition and applied at a 200 excess. For supershift (last two lanes) a rabbit serum specific for LANA was added to the binding reaction and an
unrelated rabbit antibody was used for control. The arrows mark specific shifts (right panel).
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FIG 6 Transcriptional activation or repression by LANA is not influenced by USP7 recruitment. (A to C) Representation of luciferase reporter experiments to
address the role of USP7 on LANA-mediated transcriptional activity. All results were based on duplicate samples. (A) 293-T cells were transfected with 50 ng
reporter plasmid harboring the cyclin E promoter and the indicated amounts of the LANA plasmids. Transfection of empty vectors instead of protein-encoding
plasmids served as controls. Cells were lysed 48 h posttransfection, and luciferase activity was measured. Expression of LANA constructs was verified by
immunoblotting using a human serum recognizing LANA. (B) Reporter plasmid (50 ng) harboring a p53-responsive element from the mdm2 promoter region,
200 ng p53, and the indicated amounts of full-length LANA plasmids were cotransfected in p53-negative H1299 cells. The assay was carried out as described for
panel A. (C) 293 cells were transfected with 50 ng reporter plasmid harboring the KSHV TR region in front of a luciferase gene and the indicated amounts of the
LANA plasmids. The assays were carried out as described for panel A. Expression of LANA was verified by immunoblotting using a human serum recognizing
LANA. Reporter assays shown in this figure (A to C) are representative of results of multiple experiments. Similar results were obtained when luciferase values
were normalized to those obtained with a luciferase control vector (not shown).
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assay that measures the replication of a KSHV episomal genome.
In a transient replication assay, the LANA mutant lacking the
USP7 binding site (aa 971 to 986) consistently showed increased
replication activity (Fig. 5A and B). This is in line with observa-
tions for EBNA-1, as an EBNA-1 mutant that does not bind to
USP7 was also shown to replicate the viral DNA more efficiently
(19). These findings indicate that recruitment of USP7 to LANA
can modulate latent viral DNA replication.
The increased replication activity of LANA upon deletion of
the USP7 binding site cannot be attributed to an enhanced DNA
binding ability of the mutant, as shown by EMSAs (Fig. 5C). This
is in line with the currently held notion that LANA aa 1025 to 1162
form a domain required for DNA binding and dimerization (23,
42), and the USP7 binding site identified here would therefore lie
outside this domain. The effect of USP7 on LANA-mediated viral
genome replication could have different explanations. USP7 was
shown to deubiquitinate histone H2B (41). Mono-ubiquitination
of H2B was reported to influence transcription, both positively
and negatively (12, 31, 32, 53), but effects on other processes, such
as DNA replication, cannot be excluded. A complete lack or re-
duced recruitment of USP7 to LANA could therefore influence
H2B mono-ubiquitination by either enhancing or inhibiting deu-
biquitination of H2B, which, in turn, could have an effect on viral
DNA accessibility for transcription or replication. In our hands,
the LANA 971–986 mutant showed the same ability as LANA to
activate heterologous reporters (Fig. 6A), to repress p53-mediated
transcription of the mdm2 promoter (Fig. 6B), and to act as a
transcriptional repressor of the LANA TR promoter (Fig. 6C). It
is, therefore, in our view less likely that the recruitment of USP7 to
LANA plays a role during LANA-mediated transcriptional activa-
tion or repression. Since the KSHV episome is also complexed
with histones (45, 52), USP7 could influence accessibility of the
viral DNA for latent replication or influence viral persistence me-
diated by LANA, as LANA is able to bind to histone H2B directly.
Likewise, the LANA 971–986 mutant can repress p53-depen-
dent transcription from a p53-dependent promoter to the same
extent as LANA WT. This observation suggests that the recruit-
ment of USP7 to LANA is unlikely to silence USP7, thereby mod-
ifying p53 function by increasing the amount of either ubiquiti-
nated p53 or Mdm2, the p53 E3 ligase. In conclusion, taken
together with previously published findings on the role of USP7 in
EBNA-1-dependent latent replication of EBV, our findings sug-
gest that a role of USP7 in the replication of latent viral DNA
appears to be a conserved feature among gamma-1 and gamma-2
herpesviridae.
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FIG 7 LANA homologues of other gamma-2 herpesviruses also recruit USP7. (A) HA-tagged expression constructs for the C-terminal domain of LANA (aa 934
to 1162) or the latent Orf73 protein of MHV68 and a plasmid encoding GFP-tagged USP7 were cotransfected in equal amounts (1 g each) in 293-T cells. As a
control, the corresponding empty vectors were transfected. Cells were lysed after 48 h, and protein complexes were precipitated with -HA antibody coupled to
protein G-Sepharose beads and analyzed by immunoblotting using -HA and -GFP antibodies. (B) Myc-tagged expression constructs for the C-terminal
domain of LANA (aa 934 to 1162) or the latent Orf73 protein of RRV and a plasmid encoding GFP-tagged USP7, or the appropriate control vectors, were
cotransfected in equal amounts (1 g each) in 293-T cells. Cells were lysed after 48 h, and protein complexes were precipitated with -myc antibody coupled to
agarose beads and analyzed by immunoblotting using -myc and -GFP antibodies.
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